ADMA Biologics

Aging Population And Plasma Supply Will Drive Industry Expansion

AnalystHighTarget

Not Invested

Community Contributor

Published

29 Apr 25

Updated

07 May 25

AnalystHighTarget's Fair Value

US$35.00

58.1% undervalued

10 Sep

US$14.66

-27.7%

-6.1%

-27.7%

-6.1%

You can edit this narrative until May 12 5:59 AM. Then, changes will post as Updates.

Author's Valuation

US$3558.1% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on07 May 25

AnalystHighTarget Fair Value

US$35

58.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

20.60%

Biotech revenue growth rate

8.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.81%

Calculation

US$372.21m

Earnings '28

28.05x

PE Ratio '28

US$10.44b

Market Cap '28

US$10.44b

Market Cap '28

245.48m

No. shares '28

US$42.52

Share Price '28

US$42.52 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$34.93

Fair Value '25